Pharmacogenetic Approach for the Prevention of Rivaroxaban’s ADRs: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

Row	Author and year	Population	Provenance	Study design	Sample size	Age mean (SD)	Gender male (%)	Quality assessment
1	Campos-Staffico et al., 2022 [20]	Nonvalvular atrial fibrillation patients	United States	Retrospective cohort	2364	68.3 (13.6)	1606 (67.93)	19
2	Gouin-Thibault et al., 2016 [21]	Healthy male volunteers	France	Clinical trial	60	NR	60 (100.00)	21
3	Lähteenmäki et al., 2021 [22]	Finnish rivaroxaban users	Finland	Retrospective cohort	999	69.6 (9.8)	501 (50.15)	18
4	Lenoir et al., 2022 [23]	Hospitalized rivaroxaban users	Switzerland	Prospective cohort	125	71.7 (12.1)	89 (71.20)	18
5	Nakagawa et al., 2017 [24]	Nonvalvular atrial fibrillation	Japan	Prospective cohort	86	62.4 (10.6)	73 (84.88)	20
6	Sychev et al., 2019 [25]	Patients undergoing total hip and knee replacement surgery	Russia (Moscow)	Prospective cohort	78	59 (11)	22 (28.20)	19
7	Sychev et al., 2022 [26]	Patients aged 80 years and older with nonvalvular atrial fibrillation	Russia (Moscow)	Cross-sectional	128	87.5	NR	16
8	Wang et al., 2021 [27]	Patients with atrial fibrillation	Mongolia	Retrospective cohort	155	71.98 (10.72)	81 (52.25)	19
9	Yoon et al., 2022 [28]	Patients receiving direct oral anticoagulants	Korea	Retrospective cohort	576	NR	293 (50.86)	19
10	Zhang et al., 2023 [29]	Elderly patients with nonvalvular atrial fibrillation	Korea	Prospective cohort	150	68 (12.8)	63.33	17

NR, not reported; SD, standard deviation; quality assessment based on STROBE statement; quality assessment based on CONSORT statement.